We are committed to building a major ophthalmic pharmaceutical company. Our pathway to global leadership in eye care is based on continuous scientific innovation, world-class clinical development, and company-wide operational excellence in the pursuit of novel treatments for diseases of the eye with significant unmet need.
Aerie Corporate Highlights
- Aerie Pharmaceuticals, Inc. is a publicly-traded company (NASDAQ: AERI)
- Offices
- HQ – Durham, NC
- Irvine, CA
- Bedminster, NJ
- Dublin, Ireland
- Tokyo, Japan
- Henley-on-Thames, United Kingdom
- Manufacturing Facilities
- Athlone, Ireland (cGMP sterile fill plant)
- Durham, NC (cGMP PRINT® implant production laboratory)
- Employees: Approximately 400
Aerie Product Portfolio
- Rhopressa® (netarsudil ophthalmic solution) 0.02%
- U.S. FDA approval – December 2017
- U.S. commercial launch – April 2018
- Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
- U.S. FDA approval – March 2019
- U.S. commercial launch – May 2019
- Rhokiinsa® (netarsudil 200 micrograms/ml eye drops solution)
- EU marketing authorisation – November 2019
- Roclanda® (netarsudil 200 micrograms/ml and latanoprost 50 micrograms/ml eye drops)
- EU marketing authorisation – January 2021
- Mercury 3 90-day topline results announced
- Marketing authorisation for Great Britain – April 2021
Pipeline Activities
- Globalization plan for netarsudil franchise under way
- Europe
- Commercialization planning underway
- Japan
- Phase 2 study of netarsudil completed
- Exclusive collaboration and license agreement completed with Santen for Japan and 8 other Asian nations.
- First Phase 3 trial enrollment completed; topline results Q4 2021
- Europe
- Dry Eye Disease program
- AR-15512 (TRPM8 receptor agonist eye drop)
- Phase 2b trial (COMET-1) enrollment completed; topline results Q3 2021
- AR-15512 (TRPM8 receptor agonist eye drop)
- Retinal Disease program
- AR-1105 (dexamethasone sustained release implant)
- Positive Phase 2 topline results reported July 2020
- Phase 3 planning underway in the U.S. and EU
- AR-13503 (Rho kinase/Protein kinase C inhibitor sustained release implant)
- First-in-human clinical study ongoing
- AR-14034 (Pan-VEGF receptor inhibitor sustained release implant)
- IND-enabling pre-clinical studies underway
- AR-1105 (dexamethasone sustained release implant)
- Ocular Inflammation program
- AR-6121 (Rho kinase inhibitor-linked-steroid – “ROCK’Ster”)
- IND-enabling pre-clinical studies underway
- AR-6121 (Rho kinase inhibitor-linked-steroid – “ROCK’Ster”)
- Small-molecule multi-kinase inhibitors in discovery and pre-clinical development for other ophthalmic diseases and conditions
- Proprietary library of more than 4,000 molecules
